Literature DB >> 3956335

Pathogenesis of compound 48/80-induced gastric lesions in rats.

K Takeuchi, H Ohtsuki, S Okabe.   

Abstract

Intraperitoneal administration of 0.75 mg/kg of compound 48/80 (a mast cell degranulator) once daily for four days induced extensive gastric lesions in rats. Oral administration of tripelennamine (histamine H1-receptor antagonist) and cimetidine (histamine H2-receptor antagonist) twice daily for four days had little or no effect on the lesion formation. Oral administration of methysergide and cyproheptadine (serotonin antagonists) and FPL-52694 (a mast cell stabilizer) potently inhibited the compound 48/80-induced lesions. Intraperitoneal administration of histamine plus serotonin, or serotonin alone, induced gastric lesions which resembled those induced by compound 48/80. These lesions were potently inhibited by methysergide and cyproheptadine, but not by tripelennamine, cimetidine, and FPL-52694. Single or repeated administration of compound 48/80 significantly increased serum histamine and serotonin levels. After a single administration of compound 48/80, the increased histamine levels rapidly returned to normal levels, but serotonin levels remained high for 7 hr. Histamine and serotonin levels in the gastric mucosa were transiently increased after a single administration of compound 48/80, but remained normal after repeated administration. Single or repeated administration of compound 48/80 had little effect on arterial blood pressure. The compound 48/80-induced gastric lesions appear to be caused primarily by the release of serotonin, but not histamine, from extragastric sources.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3956335     DOI: 10.1007/bf01311675

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  10 in total

1.  Induction of acute gastric lesions by histamine liberators in rats; effects thereon of pharmacologic blocking agents.

Authors:  S FRANCO-BROWDER; G M MASSON; A C CORCORAN
Journal:  J Allergy       Date:  1959 Jan-Feb

2.  A method for the fluorometric assay of histamine in tissues.

Authors:  P A SHORE; A BURKHALTER; V H COHN
Journal:  J Pharmacol Exp Ther       Date:  1959-11       Impact factor: 4.030

3.  Release of 5-hydroxytryptamine and histamine from tissues of the rat.

Authors:  J R PARRATT; G B WEST
Journal:  J Physiol       Date:  1957-07-11       Impact factor: 5.182

4.  Release of histamine by the histamine liberator compound 48/80 in cats.

Authors:  A N SMITH
Journal:  J Physiol       Date:  1953-09       Impact factor: 5.182

5.  Reduction of tissue histamine by compound 48/80.

Authors:  W FELDBERG; J TALESNIK
Journal:  J Physiol       Date:  1953-06-29       Impact factor: 5.182

6.  Effects of drugs on gastric hemorrhages produced by the administration of polymyxin B.

Authors:  O M MORENO; D A BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1962-02       Impact factor: 4.030

7.  [Drug-induced ulcer in rats. V. Serotonin].

Authors:  R Lambert; L Descos; J Pasquier; M Martin
Journal:  Gastroenterologia       Date:  1965

8.  Compound 48/80 and substance P induced release of histamine and serotonin from rat peritoneal mast cells.

Authors:  T Irman-Florjanc; F Erjavec
Journal:  Agents Actions       Date:  1983-04

9.  Characterization of FPL-52694 [5-(2-hydroxypropoxyl)-8-propyl-4-oxo-4H-benzopyran-2-carboxylic acid Na] on histamine release from rat peritoneal mast cells induced by antigen, compound 48/80 and A 23187.

Authors:  K Takeuchi; H Ohtsuki; S Nakagawa; S Okabe
Journal:  Agents Actions       Date:  1985-10

10.  Tissue distribution of histamine in a mutant mouse deficient in mast cells: clear evidence for the presence of non-mast-cell histamine.

Authors:  A Yamatodani; K Maeyama; T Watanabe; H Wada; Y Kitamura
Journal:  Biochem Pharmacol       Date:  1982-02-01       Impact factor: 5.858

  10 in total
  8 in total

1.  Relationship between changes of active oxygen metabolism and blood flow and formation, progression, and recovery of lesions is gastric mucosa of rats with a single treatment of compound 48/80, a mast cell degranulator.

Authors:  Y Ohta; T Kobayashi; K Nishida; I Ishiguro
Journal:  Dig Dis Sci       Date:  1997-06       Impact factor: 3.199

2.  A critical role of gastric mucosal ascorbic acid in the progression of acute gastric mucosal lesions induced by compound 48/80 in rats.

Authors:  Yoshio Kamiya; Yoshiji Ohta; Yoichiro Imai; Tomiyasu Arisawa; Hiroshi Nakano
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

3.  Mechanism of acid secretory changes in rat stomach after damage by taurocholate: role of nitric oxide, histamine, and sensory neurons.

Authors:  K Takeuchi; S Kato; T Yasuhiro; K Yagi
Journal:  Dig Dis Sci       Date:  1997-03       Impact factor: 3.199

4.  Serotonin causes acute gastric mucosal injury in rats, probably via 5HT1D receptors.

Authors:  S Gidener; S Apaydin; A Küpelioğlu; H Güven; A Gelal; A Güre
Journal:  Int J Exp Pathol       Date:  1995-08       Impact factor: 1.925

5.  Ketotifen ameliorates development of fibrosis in alkali burns of the esophagus.

Authors:  Vahit Yukselen; Ali Onder Karaoglu; Omer Ozutemiz; Cigdem Yenisey; Muge Tuncyurek
Journal:  Pediatr Surg Int       Date:  2004-04-24       Impact factor: 1.827

6.  Roles of in vitro- and in vivo-administered histamine and serotonin in compound 48/80-induced gastric acid secretion in isolated, perfused rat stomach.

Authors:  H C Hsu; L J Flancbaum; E Kasziba; G F Merrill; H Fisher
Journal:  Dig Dis Sci       Date:  1991-12       Impact factor: 3.199

7.  Inhibitory effect of DS-4574, a peptidoleukotriene antagonist with mast cell stabilizing action, on compound 48/80-induced gastric mucosal lesions in rats.

Authors:  Y Tabuchi; K Kawarabayashi; K Furuhama
Journal:  Agents Actions       Date:  1994-03

8.  Protective effect of ginsenoside Re on acute gastric mucosal lesion induced by compound 48/80.

Authors:  Sena Lee; Myung-Gyou Kim; Sung Kwon Ko; Hye Kyung Kim; Kang Hyun Leem; Youn-Jung Kim
Journal:  J Ginseng Res       Date:  2013-12-18       Impact factor: 6.060

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.